AW
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Oncologie. Conjugués anticorps-médicaments : une avancée pleine de défis | Revue médicale suisse |  | 2025 | 46 | 0 | ||
| Decision-making at Swissmedic, the Swiss regulatory agency, with a focus on (neo)adjuvant cancer treatments | Oncology |  | 2024 | 70 | 148 | ||
| Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022 : a comparative analysis | Lancet oncology | | 2024 | 39 | 0 | ||
| Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient | Cancer biology & therapy | | 2023 | 100 | 91 | ||
| A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration | Clinical and translational science | | 2023 | 70 | 28 |
